Log in to your Inderes Free account to see all free content on this page.
Create account

Idogen

Less than 1K followers

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

Read more
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
A bit of a price rally today, nearing 300% at best. Well, my own position is still deep in the red even if the decimal point moved one place to the right… “Discussions are being held with several stakeholders regarding the sale of Idogen’s technology platform, among other things....
6/7/2023, 9:43 AM
by Monte Cristo
3
Here’s someone who identifies as a fellow traveler, with a very similar background. However, my faith in the company is strong, and at some point, I exchanged shares for a larger number of options (TO). The option is attractively priced and currently “on sale,” as we are closer to...
2/11/2021, 4:01 PM
by Karafa
2
Fresh report, took a quick look, no surprises, losses, share issues, explanations, etc. idogen.com Idogen_Q4_EN.pdf
2/24/2023, 12:42 PM
by Monte Cristo
1
Idogen prepares to start the clinical phase 1/2a study with IDO 8 in Norway Idogen AB (publ) is intensively preparing for the company’s first clinical study with IDO 8 cell therapy in patients with severe hemophilia A and is committed to the participating research centers. In Norway...
7/29/2022, 7:46 AM
by Alisuorittaja
1
Idogen New Subscription/Share Issue https://idogen.com/idogen-offentliggor-prospekt-med-anledning-av-forestaende-foretradesemission-3/
1/28/2022, 8:46 AM
by Monte Cristo
1
Idogen AB, listed on Nasdaq Stockholm, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological drugs, transplanted organs, or the body’s own cells or tissues. The Idogen treatment method means that the patient’s blood cells develop into...
2/11/2021, 1:13 PM
by Alisuorittaja
1
Thinking Future: When the Immune System Becomes the Enemy - Idogen Nordnet Nordnet Tee säästämisestä osakkeisiin & rahastoihin hauskempaa. Sijoittaminen osakkeisiin, rahastoihin ja ETF:iin ilman tarpeettomia kuluja. Tervetuloa Suomen tyytyväisimpien sijoittajien joukkoon! Avaa tili...
8/31/2022, 8:19 PM
by Alisuorittaja
0
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.